高强度与低强度无创正压通气在慢性阻塞性肺疾病急性加重患者中的比较(HAPPEN):多中心随机对照试验研究方案
HAPPEN研究是一项多中心、两臂、单盲、前瞻性随机对照试验,计划纳入600例伴有轻中度高碳酸血症呼吸衰竭的AECOPD患者,随机接受高强度或低强度NPPV,主要终点为NPPV失败率(需气管插管有创通气)。该研究旨在探讨高强度NPPV是否比低强度NPPV更有效纠正高碳酸血症,从而减少插管需求并改善生存。
要点
- 高强度NPPV可能更有效纠正AECOPD患者的高碳酸血症。
- 主要终点为NPPV失败率,即需气管插管有创通气。
- 研究纳入600例轻中度高碳酸血症呼吸衰竭的AECOPD患者。
核心结论
- HAPPEN研究将首次通过随机对照试验验证高强度NPPV是否比低强度NPPV更有效纠正高碳酸血症、减少插管需求和死亡率。
研究设计与样本
- 多中心、两臂、单盲、前瞻性随机对照试验,纳入600例伴有轻中度高碳酸血症呼吸衰竭的AECOPD患者,按中心分层随机分配至高强度或低强度NPPV组。
关键数值与推荐
- 主要终点为NPPV失败率,定义为需气管插管和有创通气。
- 次要终点包括随机化后2小时动脉二氧化碳分压较基线的下降值、住院期间和28天死亡率、90天生存率。
- 患者随机化后随访90天。
临床怎么用
- 研究结果将帮助重症监护医生决定AECOPD患者NPPV的通气强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the positive outcomes of the use of noninvasive positive pressure ventilation (NPPV) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), NPPV fails in approximately 15% of patients with AECOPD, possibly because the inspiratory pressure delivered by conventional low-intensity NPPV is insufficient to improve ventilatory status for these patients. High-intensity NPPV, a novel form that delivers high inspiratory pressure, is believed to more efficiently augment alveolar ventilation than low-intensity NPPV, and it has been shown to improve ventilatory status more than low-intensity NPPV in stable AECOPD patients. Whether the application of high-intensity NPPV has therapeutic advantages over low-intensity NPPV in patients with AECOPD remains to be determined. The high-intensity versus low-intensity NPPV in patients with AECOPD (HAPPEN) study will examine whether high-intensity NPPV is more effective for correcting hypercapnia than low-intensity NPPV, hence reducing the need for intubation and improving survival. METHODS/DESIGN: The HAPPEN study is a multicenter, two-arm, single-blind, prospective, randomized controlled trial. In total, 600 AECOPD patients with low to moderate hypercapnic respiratory failure will be included and randomized to receive high-intensity or low-intensity NPPV, with randomization stratified by study center. The primary endpoint is NPPV failure rate, defined as the need for endotracheal intubation and invasive ventilation. Secondary endpoints include the decrement of arterial carbon dioxide tension from baseline to 2 h after randomization, in-hospital and 28-day mortality, and 90-day survival. Patients will be followed up for 90 days after randomization. DISCUSSION: The HAPPEN study will be the first randomized controlled study to investigate whether high-intensity NPPV better corrects hypercapnia and reduces the need for intubation and mortality in AECOPD patients than low-intensity NPPV. The results will help critical care physicians decide the intensity of NPPV delivery to patients with AECOPD. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02985918 . Registered on 7 December 2016.
引用
- Luo Z, Wu C, Li Q, et al. High-intensity versus low-intensity noninvasive positive pressure ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease (HAPPEN): study protocol for a multicenter randomized controlled trial. Trials. 2018. PMID: 30463622. doi:10.1186/s13063-018-2991-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。